INTELLIA THERAPEUTICS INC. - COMMON STOCK

Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

11 Jan 2023 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones

05 Jan 2023 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

30 Nov 2022 20:28:58 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

30 Nov 2022 15:36:59 By Nasdaq GlobeNewswire

Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting

12 Nov 2022 15:30:00 By Nasdaq GlobeNewswire

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022

05 Nov 2022 15:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

03 Nov 2022 06:30:01 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

31 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates

27 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present at October Healthcare Investor Conferences

26 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

16 Sep 2022 06:15:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

16 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022

08 Sep 2022 15:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

01 Sep 2022 15:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium

23 Aug 2022 08:59:42 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

04 Aug 2022 06:30:01 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates

27 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

24 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

08 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

05 May 2022 06:30:01 By Nasdaq GlobeNewswire